1
|
Conkbayir C, Ergoren M, Cobanogullari H, Balcioglu O, Abras I, Eminsel T, Oztas D, Ugurlucan M, Temel S. Associations of the ITGB3 gene rs5918T>C and the APOA1 gene rs1799837C>T markers with serum lipid metabolism in coronary artery disease patients. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aim
The relationship between hypercholesterolemia, particularly elevated low density lipoprotein-cholesterol (LDL-C) levels and coronary artery disease is recognized by the evidence from previous epidemiologic studies. Importantly, genetic polymorphisms on different genes have been reported to be associated with plasma lipid levels. In this particular study, we aimed to investigate the relationship between the ITGB3 gene rs5918 T>C and APO-A1 gene rs1799837 C>T markers and serum lipid metabolism.
Patients and methods
A total of 100 subjects with CAD and 250 healthy subjects were involved in the current study. A basic biochemical analysis, including serum glucose, total serum cholesterol, HDL-C, LDL-C and triglycerides, was performed for each participant. Genotyping for the ITGB3 gene and APO-A1 gene polymorphisms was performed by polymerase chain reaction followed by restriction fragment length polymorphism (RFLP) analysis.
Results
With respect to the genotype and allele distributions of ITGB3 rs5918 T>C polymorphism, the frequency of the C allele was higher in the coronary artery disease (CAD) group compare to control group (p=0.001). Moreover, there was a statistically significant association detected between ITGB3 rs5918 CC genotype and serum total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) (p=0.0006, p=0.016 respectively) in CAD group. However there was no statistically significant association was identified between the APOA1 rs1799837 C>T polymorphism and biochemical parameters in control and CAD group.
Conclusion
The results demonstrated that rs5918 T>C variant within the ITGB3 gene might have a clinical importance as a genetic marker which increases the susceptibility to CAD. Therefore, the ITGB3 gene rs5918 C allele may be offered as a screening option for CAD in Turkish Cypriot population who come in for medical check-up.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Near East University
Collapse
Affiliation(s)
- C Conkbayir
- Near East University, Department of Cardiology, Nicosia, Cyprus
| | - M Ergoren
- Near East University, Department of Genetics, Nicosia, Cyprus
| | - H Cobanogullari
- Near East University, department of Medical Biology, Nicosia, Cyprus
| | - O Balcioglu
- Near East University, Cardiovascular surgery, Nicosia, Cyprus
| | - I Abras
- Eastern Mediterrenean University, Biological sciences, Famagusta, Cyprus
| | - T Eminsel
- Eastern Mediterrenean University, Biological sciences, Famagusta, Cyprus
| | - D Oztas
- Bagcilar Education and Research Hospital, Cardiovascular surgery, Isanbul, Turkey
| | - M Ugurlucan
- Istanbul Medipol University, Cardiovascular department, Istanbul, Turkey
| | - S Temel
- Uludag University, Genetic Department, Bursa, Turkey
| |
Collapse
|
2
|
Wahl GM, Ma Z, Chung C, Dravis C, Spike BT, Giraddi RT, Balcioglu O, Fan C, Hagos B, Heinz R, Herrera-Valdez J, Hou X, Hwang J, Lasken R, Luna G, Lytle NE, Mehrabad EM, Novotny M, Perou CM, Poirion O, Preissl S, Ren B, Reya T, Trejo CL, Varley KT. Abstract ES10-2: Understanding breast cancer using a developmental perspective. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-es10-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Parallels among embryonic development, stem cells, and cancer have long been recognized. We identified, isolated, and characterized stem cells that first become committed to a mammary fate during embryogenesis; we refer to these cells as fetal mammary stem cells (fMaSCs). Lineage tracing, in vitro sphere formation, and in vivo transplantation studies by our group and many others all confirm that cells in the embryo are the bipotent progenitors of the mammary gland. There is debate, however, on whether such bipotent cells persist into the adult, or whether the luminal and basal lineages are maintained by unipotent progenitors. To gain insight into the relationships between fMaSCs and breast cancer, and to investigate their potential persistence in the adult, we have applied bulk and single cell RNA-sequencing (sc-RNA-seq) and single nucleus ATAC-sequencing (snATAC-seq) throughout mammary development. The results to be discussed demonstrate that fMaSC transcriptomes are heterogeneous, but all share co-expression of genes associated with luminal and basal cell fates. This fits a model in which the bipotent state is created by a balance of lineage specifiers. We also find that the fMaSC transcriptome is highly enriched in basal-like human breast cancers and identify potential embryonic pathways that correlate with poor prognosis. We used a variety of computational tools to infer the gene expression programs that ensue when fMaSCs commit to luminal and basal states. The data from scRNA-seq and snATAC-seq demonstrate that the transitions are gradual, not precipitous, and that luminal and basal cells exhibit significant transcriptomic and epigenetic heterogeneity. This challenges the notion that the mammary gland consists of discrete cell types defined by rigid transcriptomic parameters, and reveals a potential for intrinsic phenotypic plasticity of normal mammary cells. Using the combined databases, we identified Sox10 as a significantly differentially expressed cell state regulator. We show that tumors are heterogeneous with regard to Sox10 expression, and that locally invasive cells tend to express high Sox10 levels. Elevated Sox10 correlates with acquisition of a neural-crest like, EMT-related state. Implications for interception of metastasis by targeting neural crest-like cells will be discussed. Finally, we have generated a web resource that is available to the scientific community to enable the transcription and epigenetic characteristics of any gene of interest to be tracked through mammary development (https://wahl-labsalk.shinyapps.io/Mammary_snATAC/).
Citation Format: GM Wahl, Z Ma, C Chung, C Dravis, BT Spike, RR Giraddi, O Balcioglu, C Fan, B Hagos, R Heinz, Herrera-Valdez J, X Hou, J Hwang, R Lasken, G Luna, NE Lytle, EM Mehrabad, M Novotny, CM Perou, O Poirion, S Preissl, B Ren, T Reya, CL Trejo, KT Varley. Understanding breast cancer using a developmental perspective [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr ES10-2.
Collapse
Affiliation(s)
- GM Wahl
- 1Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA
| | - Z Ma
- 1Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA
| | - C Chung
- 2Gene Expression Laboratory, Salk Institute for Biological Studies; Current address: Pfizer Inc., San Diego, CA 92121, La Jolla, CA
| | - C Dravis
- 1Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA
| | - BT Spike
- 3Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, UT
| | - RT Giraddi
- 2Gene Expression Laboratory, Salk Institute for Biological Studies; Current address: Pfizer Inc., San Diego, CA 92121, La Jolla, CA
| | - O Balcioglu
- 3Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, UT
| | - C Fan
- 4Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - B Hagos
- 3Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, UT
| | - R Heinz
- 5Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake Sity, UT
| | - J Herrera-Valdez
- 1Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA
| | - X Hou
- 6Center for Epigenomics, Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, CA
| | - J Hwang
- 3Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, UT
| | - R Lasken
- 7J. Craig Venter Institute, La Jolla, CA
| | - G Luna
- 1Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA
| | - NE Lytle
- 1Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA
| | - EM Mehrabad
- 3Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, UT
| | - M Novotny
- 7J. Craig Venter Institute, La Jolla, CA
| | - CM Perou
- 4Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - O Poirion
- 6Center for Epigenomics, Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, CA
| | - S Preissl
- 6Center for Epigenomics, Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, CA
| | - B Ren
- 8Center for Epigenomics, Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine; Ludwig Institute for Cancer Research, La Jolla, CA
| | - T Reya
- 9Sanford Consortium for Regenerative Medicine; Departments of Pharmacology and Medicine, Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA
| | - CL Trejo
- 1Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA
| | - KT Varley
- 3Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, UT
| |
Collapse
|
3
|
Balcioglu O, Ertugay S, Ozturk P, Engin C, Nalbantgil S, Nalbantgil S, Yagdi T, Ozbaran M. Risk Factors of Gastrointestinal Bleeding after Continuous Flow Left Ventricular Assist Device. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Ertugay S, Engin C, Nalbantgil S, Kocabaş S, Balcioglu O, Engin Y, Yagdi T, Ozbaran M. Postoperative Outcomes of the Largest HeartMate-II Experience in Turkey. Transplant Proc 2016; 47:1499-502. [PMID: 26093751 DOI: 10.1016/j.transproceed.2015.04.046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
INTRODUCTION HeartMate II (HMII; Thoratec Corporation, Pleasanton, Calif, United States) is a continuous-flow pump approved by the Food and Drug Administration (FDA) for bridge-to-transplantation (BTT) since 2008 and for destination therapy (DT) since 2010. Herein, we present the postoperative outcomes of HMII implantation due to end-stage heart failure in our center. METHODS Twenty-eight patients (mean age, 51.2 ± 8.7 years; 1 female) were implanted with the HMII between August 2012 and August 2014. Indications were dilated (n = 18) and ischemic (n = 10) cardiomyopathy. The intended treatment was BTT in 24 and DT in 4 patients. Preoperative clinical status was International Registry for Mechanical Circulatory Support (INTERMACS) 2, 3, and 4 in 6, 14, and 8 patients, respectively. The procedure was performed via conventional sternotomy under cardiopulmonary bypass. Heparin, acetylsalicylic acid, and warfarin were used for postoperative anticoagulation. RESULTS Mean duration of support was 326 days (median, 272). Three patients underwent heart transplantation and 22 remain on pump support. One patient died before discharge due to respiratory failure and 2 others died following a cerebral bleeding 248 and 265 days postoperatively, respectively. The survival rates at 6 and 12 months were 96% and 90%, respectively. Temporary right ventricular failure was observed in 2 patients. Two patients had pump thrombosis treated with anticoagulation management or pump exchange, whereas another patient who had aortic root thrombosis underwent reoperation for removal of the thrombus. DISCUSSION Mechanical circulatory support with HMII axial flow pump seems to be effective and may provide good survival rates compared with optimum medical management and old-generation devices. Patient selection and timing of implantation are crucial for success.
Collapse
Affiliation(s)
- S Ertugay
- Cardiovascular Surgery Department, Ege University Medical Faculty, Izmir, Turkey.
| | - C Engin
- Cardiovascular Surgery Department, Ege University Medical Faculty, Izmir, Turkey
| | - S Nalbantgil
- Department of Cardiology, Ege University Medical Faculty, Izmir, Turkey
| | - S Kocabaş
- Department of Anesthesiology, Ege University Medical Faculty, Izmir, Turkey
| | - O Balcioglu
- Cardiovascular Surgery Department, Ege University Medical Faculty, Izmir, Turkey
| | - Y Engin
- Department of Cardiovascular Surgery, Tepecik Research and Training Hospital, Izmir, Turkey
| | - T Yagdi
- Cardiovascular Surgery Department, Ege University Medical Faculty, Izmir, Turkey
| | - M Ozbaran
- Cardiovascular Surgery Department, Ege University Medical Faculty, Izmir, Turkey
| |
Collapse
|
5
|
Balcioglu O, Ertugay S, Bozkaya H, Parildar M, Posacioglu H. Endovascular Repair and Adjunctive Immunosuppressive Therapy of Aortic Involvement in Behçet's Disease. Eur J Vasc Endovasc Surg 2015; 50:593-8. [PMID: 26321000 DOI: 10.1016/j.ejvs.2015.07.011] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Accepted: 07/08/2015] [Indexed: 11/27/2022]
Abstract
OBJECTIVES Aortic aneurysm is a serious problem in Behçet's disease, but open surgical therapy carries the risk of recurrent pseudoaneurysm. Here the outcomes of endovascular repair and adjunctive immunosuppressive therapy for aortic disease in Behçet's disease are presented. MATERIALS This was a retrospective study. Between 2002 and 2012, nine patients with Behçet's disease (8 male, median age 41 years, range 33-60 years) were treated by endovascular stent grafting for abdominal or thoraco-abdominal aortic pseudoaneurysm. METHODS Computed tomography angiography revealed infrarenal pseudoaneurysm in six (66.6%) patients and suprarenal pseudoaneurysm in three (33.3%). Patients received immunosuppressive therapy with oral prednisolone (60 mg/day) and cyclophosphamide (200 mg/day) for 2 weeks or more before the procedure, and intravenous hydrocortisone (200 mg/day) combined with cyclophosphamide (200 mg/day) for 3 days after the procedure. Thereafter, oral immunosuppressive therapy was continued for 2 years. RESULTS A straight tube graft was implanted in seven patients and a bifurcated graft in two patients. Two stage procedures (debranching before endovascular therapy) were performed in three patients for thoraco-abdominal aortic pseudoaneurysms. Stent grafting was successful in all patients, without any peri-operative complications. However, two patients needed abdominal exploration later: one for seroma around the graft and the other for a fistula between the duodenum and the graft. No recurrence of aneurysm was observed during a mean follow up of 40 ± 16 months. One patient died in the 15th month from a non-vascular cause. CONCLUSIONS Endovascular stent graft implantation and adjunctive immunosuppressive therapy seems to be safe and effective in the treatment of aortic involvement in Behçet's disease, but this approach needs further evaluation.
Collapse
Affiliation(s)
- O Balcioglu
- Department of Cardiovascular Surgery, Near East University, North Cyprus, Cyprus
| | - S Ertugay
- Department of Cardiovascular Surgery, Ege University Medical Faculty Hospital, Izmir, Turkey.
| | - H Bozkaya
- Department of Radiology, Ege University Medical Faculty Hospital, Izmir, Turkey
| | - M Parildar
- Department of Radiology, Ege University Medical Faculty Hospital, Izmir, Turkey
| | - H Posacioglu
- Department of Cardiovascular Surgery, Ege University Medical Faculty Hospital, Izmir, Turkey
| |
Collapse
|
6
|
Ozbaran M, Yagdi T, Engin C, Erkul S, Balcioglu O, Baysal B, Nalbantgil S, Ertugay S. Long-term paracorporeal ventricular support systems: a single-center experience. Transplant Proc 2013; 45:1013-6. [PMID: 23622611 DOI: 10.1016/j.transproceed.2013.02.073] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The Berlin Heart EXCOR is a first-generation paracorporeal, pneumatic ventricular assist device that creates pulsatile flow. It can be used for long-term support of the left and/or right ventricule during end-stage heart failure. The aim of this study was to share our clinical experience in 54 patients. METHODS Between April 2007 and August 2012, 54 patients with end-stage heart failure underwent Berlin Heart EXCOR ventricular assist device implantation, including 5 females and 9 children. Twenty-four patients (44%) were in Intermacs level 1, 11 (21%) in level 2, and 19 (35%) in level 3. Biventricular support was applied to 13 patients. Device implantation was performed with an "on pump" beating heart technique while 6 other patients underwent intervention operations while the aortic valve has under cross-clamp. Tricuspid annuloplasty was performed in 6 patients. RESULTS There was no peroperative death. Nine patients (17%) underwent re-exploration because of hemorrhage in the early postoperative period. Heart transplantation was performed in 32 patients (59%), while 10 (19%) are still under pump support with a mean follow-up of 13 months. Although 1 was successfully weaned from the system, 11 patients (20%) died during the support. Pump-head exchange was required 19 times in 17 patients because of visible thrombus or fibrin deposit in the pump head or due to membrane rupture. DISCUSSION The use of long-term paracorporeal assist devices has decreased in recent years because of the increased popularity of implantable devices that permit longer survival and a better quality of life. We believe that the Berlin Heart EXCOR has a special role because it can be used in pediatric patients and especially in critical conditions like Intermacs levels 1 and 2.
Collapse
Affiliation(s)
- M Ozbaran
- Departments of Cardiovascular Surgery and Cardiology, Ege University Medical Faculty, Izmir, Turkey
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Engin C, Yagdi T, Balcioglu O, Erkul S, Baysal B, Oguz E, Ayik F, Ozturk P, Ozbaran M. Left Ventricular Assist Device Implantation in Heart Failure Patients With a Left Ventricular Thrombus. Transplant Proc 2013; 45:1017-9. [DOI: 10.1016/j.transproceed.2013.02.071] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
8
|
Ozturk C, Ayik F, Oguz E, Ozturk P, Karapolat H, Balcioglu O, Yagdi T, Engin C, Ozbaran M. Evaluation of changes in quality of life among Turkish patients undergoing ventricular assist device implantation. Transplant Proc 2012; 44:1735-7. [PMID: 22841258 DOI: 10.1016/j.transproceed.2012.05.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND Ventricular assist device (VAD) application has become an increasingly common method to treatment end-stage heart failure. In this study we evaluated the effect of VAD implantation upon the quality of life among Turkish patients with end-stage heart failure. METHODS Twenty-eight VAD implantation patients included 3 (10.7%) with biventricular support using the Berlin Heart Excor; 15 (53.6%), left ventricular support with the Berlin Heart Excor; and 10 (35.7%), Heartware implantation for left ventricular support. The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Short Form 36 (SF-36) Health Questionnaire were used to assess changes in the quality of life (QOL). RESULTS Of the 28 patients, 2 were females (7.1%) and 26 were males (92.9%) of overall mean age of 44.6 ± 15.3 years (range, 8-66). Preoperative mean score of MLHFQ was significantly improved at 200.4 ± 147.4 days follow-up (72.8 ± 11.5 vs 13.7 ± 10.5; P < .05). SF-36 physical scores and mental scores were improved postoperatively (physical scores, 20.0 ± 24.4 vs 70.2 ± 19.9; mental scores, 38.4 ± 18.8 vs 73.9 ± 15.7; P < .05). No significant relation was observed between the postoperative scores of questionnaires and type of surgery. More improvement in postoperative MLHFQ scores was seen in patients younger than 45 years of age (P = .027). The severity of chronic heart failure (CHF) regressed from New York Heart Association (NYHA) class IV to NYHA class II in 26 and to NYHA class III in 2 patients (P = .000). CONCLUSION The QOL among patients with end-stage heart failure improved dramatically soon after VAD implantation.
Collapse
Affiliation(s)
- C Ozturk
- Department of Physical Therapy and Rehabilitation, Medical Faculty, Ege University, Izmir, Turkey
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Güneş Y, Seçen M, Ozcengiz D, Gündüz M, Balcioglu O, Işik G. Comparison of caudal ropivacaine, ropivacaine plus ketamine and ropivacaine plus tramadol administration for postoperative analgesia in children. Paediatr Anaesth 2004; 14:557-63. [PMID: 15200652 DOI: 10.1111/j.1460-9592.2004.01220.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND The aim of this study was to compare the effect of single-dose caudal ropivacaine, ropivacaine plus ketamine and ropivacaine plus tramadol in children for postoperative pain management. METHODS Following ethics committee approval and informed parental consent, 99 ASA PS I or II children, between 1 and 10 years of age, scheduled for elective inguinal hernia repair with general anaesthesia, were recruited. After induction of anaesthesia and placement of a laryngeal mask airway (LMATM), the patients were randomly divided into three groups to receive either caudal ropivacaine alone (0.4%, 2 mg x kg(-1)) in group R (n = 32) or ropivacaine (0.2%, 1 mg x kg(-1)) plus ketamine (0.25 mg x kg(-1)) in group RK (n = 33) or ropivacaine (0.2%, 1 mg x kg(-1)) plus tramadol (1 mg x kg(-1)) in group RT (n = 34) with a total volume of 0.5 ml x kg(-1). Systemic blood pressure (SBP and DBP), heart rate (HR), peripheral O2 saturation (SpO2), respiratory rate (RR), sedation and pain scores were recorded at 5, 10, 15 and 30 min, 1, 3, 4 and 6 h following recovery from anaesthesia. Pain was evaluated by Children's Hospital of Eastern Ontario Pain Scale, and sedation with a five-point sedation test. RESULTS No difference was found regarding age, weight and duration of operation between the groups (P > 0.05). No patient experienced hypotension, bradycardia or respiratory depression. Duration of analgesia was longer in group RT (1377 +/- 204 min) than group R (1006 +/- 506 min) (P = 0.001). In the tramadol group, fewer patients required supplementary analgesics in the first 24 h (P = 0.005). Sedation scores were below 2 in all groups. Incidence of postoperative nausea and vomiting was higher in group RT (eight patients) and group RK (seven patients) than group R (one patient, P = 0.032). CONCLUSIONS Ropivacaine (0.4%), ropivacaine (0.2%) plus ketamine (0.25 mg x kg(-1)) and ropivacaine (0.2%) plus tramadol (0.5 mg x kg(-1)) provided sufficient analgesia in children, but the duration of analgesia was longer in the RT group.
Collapse
Affiliation(s)
- Y Güneş
- Department of Anaesthesiology, Faculty of Medicine, Cukurova University, Adana, Turkey
| | | | | | | | | | | |
Collapse
|